Find Clinical Trial

Home » Find Clinical Trials » Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.

Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.

← Back

Study Phase	Phase 2

Therapeutic Area	Neuropsychiatric Diseases

Indication	Mild Cognitive Impairment

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S018986

Active Substance Code	S018986

Protocol Code	CL2-18986-009

EudraCT Code	2004-004327-35

NCT Code	NCT00202540

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.